CLAIM AMENDMENTS

In the Claims:

Please cancel claims 3-17. Please enter new claims 20-48 and amend claim 1 as follows:

---

1. (currently amended) ~~A process for delivering a polymer to a cell, *in vivo*, comprising:~~
   ~~a) assisting delivery to the cell by electrostatically associating a chelator with the polymer;~~
   ~~b) delivering the polymer to the inside of the cell; and,~~
   ~~c) expressing the polymer.~~

   A process for delivering a polynucleotide to a cell comprising:

   a) forming a complex consisting of a polynucleotide and a chelator, wherein electrostatic interaction of the chelator with one or more components of the complex requires the presence of a metal ion coordinated by the chelator; and,

   b) delivering the complex to the cell.

2-17. (canceled)

18. (withdrawn)

19. (withdrawn)

Cl 20. (new) The process of claim 1 wherein the chelator consists of a polychelator.

21. (new) The process of claim 1 wherein the chelator consists of a crown ether.

22. (new) The process of claim 20 wherein a plurality of chelators is covalently linked to a polymer.

23. (new) The process of claim 20 wherein the polychelator is formed by covalently polymerizing chelator monomers.

24. (new) The process of claim 20 wherein the polychelator condenses the polynucleotide.

25. (new) The process of claim 24 wherein condensation of the polynucleotide requires the presence of cations.

26. (new) The process of claim 1 wherein the chelator is covalently linked to a compound selected from the list consisting of: a hydrophobic group, a cell receptor signal, a releasing signal, and a steric stabilizer.

27. (new) The process of claim 1 wherein the polynucleotide is expressible.

28. (new) The process of claim 29 wherein the polynucleotide expresses a therapeutic gene.

29. (new) The process of claim 1 wherein the cell consists of an *in vivo* mammalian cell.

30. (new) A process for delivery of a polynucleotide to a cell comprising:

    a) forming a complex consisting of a polynucleotide, a primary amine-containing molecule and a chelator wherein the chelator forms a coordinate bond with the amine on the molecule; and,

    b) delivering the complex to the cell.

31. (new) The process of claim 30 wherein the chelator consists of a crown ether.

32. (new) The process of claim 30 wherein the primary amine-containing molecule is a polyamine.

33. (new) The process of claim 30 wherein the primary amine-containing molecule is a polycation.

34. (new) The process of claim 30 wherein the chelator consists of a polychelator.

35. (new) The process of claim 34 wherein the polychelator consists of a polyanion.

36. (new) The process of claim 35 wherein the polyanion recharges the complex to give the complex a negative surface charge.

Cl cont

37. (new) The process of claim 34 wherein the polychelator consists of a polycation.

38. (new) The process of claim 30 wherein the chelator is covalently linked to a compound selected from the list consisting of: a cell targeting signal, a releasing signal, and a hydrophobic group.

39. (new) The process of claim 30 wherein the primary amine-containing molecule is selected from the list consisting of: a cell receptor signal, a releasing signal, a hydrophobic group and a steric stabilizer.

40. (new) The process of claim 30 wherein the polynucleotide is expressible.

41. (new) The process of claim 40 wherein the polynucleotide expresses a therapeutic gene.

42. (new) The process of claim 30 wherein the cell consists of an *in vivo* mammalian cell.

43. (new) A process for delivering a polynucleotide to a cell comprising:

    a) forming a complex consisting of a polynucleotide, a first molecule and a second molecule wherein one or more chelators are covalently linked to the first molecule, one or more chelators are covalently linked to the second molecule, and coordination of a metal ion by one or more of the chelators stabilizes the interaction between the first molecule and the second molecule; and,

    b) delivering the complex to the cell.

44. (new) The process of claim 43 wherein the first molecule consists of a polycation and the second molecule consists of a polyanion.

45. (new) The process of claim 43 wherein the first molecule consists of a polycation, and the second molecule is selected from the list consisting of a cell receptor signal, a releasing signal, a hydrophobic group and a steric stabilizer.

46. (new) The process of claim 30 wherein the polynucleotide is expressible.

47. (new) The process of claim 40 wherein the polynucleotide expresses a therapeutic gene.

48. (new) The process of claim 30 wherein the cell consists of an *in vivo* mammalian cell.